Last reviewed · How we verify
MPC-6827
At a glance
| Generic name | MPC-6827 |
|---|---|
| Sponsor | Myrexis Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Exploratory Evaluation of [11C]MPC6827 (EARLY_PHASE1)
- Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE2)
- Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme (PHASE2)
- Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme (PHASE1, PHASE2)
- Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma (PHASE1, PHASE2)
- Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors (PHASE1)
- Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPC-6827 CI brief — competitive landscape report
- MPC-6827 updates RSS · CI watch RSS
- Myrexis Inc. portfolio CI